Why the study?
Does trimetazidine improve left ventricular systolic function and physical tolerance in patients with ischaemic cardiomyopathy?
Population
82 consecutive patients with ischaemic cardiomyopathy
Comparison
Trimetazidine 35 mg twice daily added to… vs Conventional therapy alone
Design
Cohort
Follow-up
3 months
Authors
Loading...
Trimetazidine addition was associated with modest gains in ischaemic cardiomyopathy; hypothesis-generating and requires randomized confirmation before practice change.
Does trimetazidine improve left ventricular systolic function and physical tolerance in patients with ischaemic cardiomyopathy?
The addition of trimetazidine to standard therapy for 3 months modestly improves left ventricular ejection fraction and exercise capacity in patients with ischaemic cardiomyopathy.
Sisakian et al. (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: